The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis
Open accessAbstract
Growth differentiation factor (GDF) 15 is a member of the transforming growth factor β (TGF-β) superfamily, which operates in acute phase responses through a currently unknown receptor. Elevated GDF-15 serum levels were recently identified as a risk factor for acute coronary syndromes. We show that GDF-15 expression is up-regulated as disease progresses in murine atherosclerosis and primarily colocalizes with plaque macrophages. Hematopoietic GDF-15 deficiency in low density lipoprotein receptor−/− mice led to impaired initial lesion formation and increased collagen in later lesions. Although lesion burden in GDF-15−/− chimeras was unaltered, plaques had reduced macrophage infiltrates and decreased necrotic core formation, all features of improved plaque stability. In vitro studies pointed to a TGFβRII-dependent regulatory role of GDF-15 in cell death regulation. Importantly, GDF-15−/− macrophages displayed reduced CCR2 expression, whereas GDF-15 promoted macrophage chemotaxis in a strictly CCR2- and TGFβRII-dependent manner, a phenomenon which was not observed in G protein–coupled receptor kinase 2+/− macrophages. In conclusion, GDF-15 deletion has a beneficial effect both in early and later atherosclerosis by inhibition of CCR2-mediated chemotaxis and by modulating cell death. Our study is the first to identify GDF-15 as an acute phase modifier of CCR2/TGFβRII-dependent inflammatory responses to vascular injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tacke, F., Alvarez, D., Kaplan, T. J., Jakubzick, C., Spanbroek, R., Llodra, J., Garin, A., Liu, J., Mack, M., van Rooijen, N., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28549 · Cited by 1,323
Kempf, T., Eden, M., Strelau, J., Naguib, M., Willenbockel, C., Tongers, J., Heineke, J., Kotlarz, D., Xu, J., Molkentin, J. D., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000202805.73038.48 · Cited by 651
Thorp, E., Cui, D., Schrijvers, D. M., Kuriakose, G., & Tabas, I. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.167197 · Cited by 357
Hsiao, E. C., Koniaris, L. G., Zimmers-Koniaris, T., Sebald, S. M., Huynh, T. V., & Lee, S.-J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.10.3742-3751.2000 · Cited by 302
Self-citationSchlittenhardt, D., Schober, A., Strelau, J., Bonaterra, G. A., Schmiedt, W., Unsicker, K., Metz, J., & Kinscherf, R. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0986-3 · Cited by 224
Ait-Oufella, H., Pouresmail, V., Simon, T., Blanc-Brude, O., Kinugawa, K., Merval, R., Offenstadt, G., Lesèche, G., Cohen, P. L., Tedgui, A., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.169078 · Cited by 187 · cited 2×
“that defective clearance of apoptotic cells by macrophages leads to increased necrotic core formation and inflammation in atherosclerotic lesions (Ait-Oufella et al., 2008; Thorp et al., 2008), the minor effect on phagocytosis we observe is not likely to influence plaque inflammation and necrosis.”
Cited by
GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates
Mullican, S. E., Lin-Schmidt, X., Chin, C.-N., Chavez, J. A., Furman, J. L., Armstrong, A. A., Beck, S. C., South, V. J., Dinh, T. Q., Cash-Mason, T. D., et al. (2017) · Nature Medicine · doi:10.1038/nm.4392 · Cited by 774
Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease
Wollert, K. C., Kempf, T., & Wallentin, L. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.255174 · Cited by 559
Kempf, T., Zarbock, A., Widera, C., Butz, S., Stadtmann, A., Rossaint, J., Bolomini-Vittori, M., Korf-Klingebiel, M., Napp, L. C., Hansen, B., et al. (2011) · Nature Medicine · doi:10.1038/nm.2354 · Cited by 518
GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease
Wang, D., Day, E. A., Townsend, L. K., Djordjevic, D., Jørgensen, S. B., & Steinberg, G. R. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00529-7 · Cited by 516
Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study
Wang, T. J., Wollert, K. C., Larson, M. G., Coglianese, E., McCabe, E. L., Cheng, S., Ho, J. E., Fradley, M. G., Ghorbani, A., Xanthakis, V., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.129437 · Cited by 482
Adela, R., & Banerjee, S. K. (2015) · Journal of Diabetes Research · doi:10.1155/2015/490842 · Cited by 474
“Inhibition of high glucose-induced p53 accumulation by p53 siRNA abolished GDF-15 induction [5].”
BackgroundCytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets
Ramji, D. P., & Davies, T. S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.04.003 · Cited by 469
Molecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 459
Tsai, V. W. W., Husaini, Y., Sainsbury, A., Brown, D. A., & Breit, S. N. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.018 · Cited by 409
Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets
Chen, R., Zhang, H., Tang, B., Luo, Y., Yang, Y., Zhong, X., Chen, S., Xu, X., Huang, S., & Liu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01840-1 · Cited by 349
Inflammation and immune system interactions in atherosclerosis
Legein, B., Temmerman, L., Biessen, E. A. L., & Lutgens, E. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1289-1 · Cited by 292
Self-citationInflammation induced loss of skeletal muscle
Londhe, P., & Guttridge, D. C. (2015) · Bone · doi:10.1016/j.bone.2015.03.015 · Cited by 276
Unsicker, K., Spittau, B., & Krieglstein, K. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.05.003 · Cited by 274
GDF15: a hormone conveying somatic distress to the brain
Lockhart, S. M., Saudek, V., & O’Rahilly, S. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa007 · Cited by 256
Breit, S. N., Johnen, H., Cook, A. D., Tsai, V. W. W., Mohammad, M. G., Kuffner, T., Zhang, H. P., Marquis, C. P., Jiang, L., Lockwood, G., et al. (2011) · Growth Factors · doi:10.3109/08977194.2011.607137 · Cited by 247
Growth Differentiation Factor 15 as a Novel Biomarker for Metformin
Gerstein, H. C., Pare, G., Hess, S., Ford, R. J., Sjaarda, J., Raman, K., McQueen, M., Lee, S., Haenel, H., & Steinberg, G. R. (2017) · Diabetes Care · doi:10.2337/dc16-1682 · Cited by 169
Self-citationGuo, Y., Ayers, J. L., Carter, K. T., Wang, T., Maden, S. K., Edmond, D., Newcomb P, P., Li, C., Ulrich, C., Yu, M., et al. (2019) · Aging Cell · doi:10.1111/acel.13013 · Cited by 139
Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond
Mullican, S. E., & Rangwala, S. M. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.05.002 · Cited by 127
Overview of growth differentiation factor 15 in metabolic syndrome
Asrih, M., Wei, S., Nguyen, T. T., Yi, H., Ryu, D., & Gariani, K. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17725 · Cited by 70
Metadata
- Authors
- de Jager, S. C. A., Bermúdez, B., Bot, I., Koenen, R. R., Bot, M., Kavelaars, A., de Waard, V., Heijnen, C. J., Muriana, F. J. G., Weber, C., van Berkel, T. J. C., Kuiper, J., Lee, S.-J., Abia, R., & Biessen, E. A. L.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2011-01-17
- Volume
- 208
- Issue
- 2
- Pages
- 217-225
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2160347285
- Cited by
- 222
- References
- 6
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.